

N (6)-substituted AMPs inhibit mammalian deoxynucleotide N-hydrolase DNPH1.

Claire Amiable, Sylvie Pochet, André Padilla, Gilles Labesse,

Pierre-Alexandre Kaminski

► To cite this version:

Claire Amiable, Sylvie Pochet, André Padilla, Gilles Labesse, Pierre-Alexandre Kaminski. N (6)-substituted AMPs inhibit mammalian deoxynucleotide N-hydrolase DNPH1.. PLoS ONE, 2013, 8 (11), pp.e80755. 10.1371/journal.pone.0080755.t003. pasteur-01472730

HAL Id: pasteur-01472730 https://pasteur.hal.science/pasteur-01472730

Submitted on 21 Feb 2017

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers. L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



Distributed under a Creative Commons Attribution 4.0 International License

*N*⁶-Substituted AMPs Inhibit Mammalian Deoxynucleotide *N*-Hydrolase DNPH1

Claire Amiable^{1,2,3}, Sylvie Pochet^{1,2}, André Padilla^{4,5,6}, Gilles Labesse^{4,5,6}, Pierre Alexandre Kaminski^{1,2*}

1 Institut Pasteur, Unité de Chimie et Biocatalyse, Paris, France, 2 CNRS, UMR3523, Paris, France, 3 Université Paris Descartes Sorbonne Paris Cité, Paris, France, 4 CNRS, UMR5048, Centre de Biochimie Structurale, Montpellier, France, 5 INSERM, U554, Montpellier, France, 6 Université Montpellier 1 et 2; IFR3, Montpellier, France

Abstract

The gene *dnph1* (or *rcl*) encodes a hydrolase that cleaves the 2'-deoxyribonucleoside 5'-monophosphate (dNMP) *N*-glycosidic bond to yield a free nucleobase and 2-deoxyribose 5-phosphate. Recently, the crystal structure of rat DNPH1, a potential target for anti-cancer therapies, suggested that various analogs of AMP may inhibit this enzyme. From this result, we asked whether *N*⁶-substituted AMPs, and among them, cytotoxic cytokinin riboside 5'-monophosphates, may inhibit DNPH1. Here, we characterized the structural and thermodynamic aspects of the interactions of these various analogs with DNPH1. Our results indicate that DNPH1 is inhibited by cytotoxic cytokinins at concentrations that inhibit cell growth.

Citation: Amiable C, Pochet S, Padilla A, Labesse G, Kaminski PA (2013) N⁶-Substituted AMPs Inhibit Mammalian Deoxynucleotide *N*-Hydrolase DNPH1. PLoS ONE 8(11): e80755. doi:10.1371/journal.pone.0080755

Editor: Diego Fraidenraich, Rutgers University -New Jersey Medical School, United States of America

Received August 5, 2013; Accepted October 15, 2013; Published November 19, 2013

Copyright: © 2013 Amiable et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Funding: This work was financially supported by the Institut Pasteur, CNRS, Fondation pour la Recherche Medicale (DCM20111223063 to S. Pochet) and by the French Infrastructure for Integrated Structural Biology (FRISBI) ANR-10-INSB-05-01. C. Amiable was recipient of a fellowship from the French Ministry of Research. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing interests: The authors have declared that no competing interests exist.

* E-mail: pierre-alexandre.kaminski@pasteur.fr

Introduction

Nucleoside analogs are widely used in chemotherapy to fight against cancer and viral infections. Most of the anticancer nucleoside analogs exert their effect after incorporation into DNA. They interfere with one or more enzymes that are critical for DNA synthesis or DNA repair and cause DNA damage then apoptosis induction [1]. For example, purine analogs such as Fludarabine, Cladribine and Clofarabine used in the treatment of leukemia, are efficiently incorporated into DNA to act as chain terminators, but the latter two are also potent inhibitors of ribonucleotide reductase [2].

In fact, multiple steps of the nucleotide biosynthesis may also be targeted upstream from DNA synthesis and repair and multitarget strategy may help in preventing drug resistance.

The plant hormone cytokinins are adenine derivatives with an isoprenoid or an aromatic side chain substituted at the N6 position. For instance, N^6 -isopentenyladenosine, N^6 furfuryladenosine (kinetin riboside) and N^6 -benzyladenosine have cytotoxic effects for different human cell lines derived from solid tumours [3–10]. These compounds also show good efficiency *in vivo* using several animal and xenograft models of cancer [4,5,11,12]. However, their actual cellular targets are unknown. While cytokinin bases induce differentiation at relatively high concentrations, their ribosides cause rapid apoptosis of leukaemia cell lines at low micro-molar concentrations [13]. Intracellular conversion of ribosides to their respective 5'-monophosphates by adenosine kinase is known to be required for their action [14–16]. This mode of activation resembles that of the triciribine, another pro-apoptotic nucleoside that is currently in phase I trials [17]. While the PH domain of Akt has been proposed as a target for triciribine 5'-monophosphate, we have recently shown that this compound also inhibits DNPH1 [18]. DNPH1 is a potential target for anti-cancer therapies as it is involved in cellular proliferation [19,20] and is up-regulated in several types of cancer [21–23].

DNPH1 is a 2'-deoxynucleoside 5'-phosphate *N*-hydrolase. It hydrolyses dNMP to form a free nucleobase moiety and 2-deoxyribose 5-phosphate [24]. The nucleotide binding and catalytic sites were probed with various synthetic nucleotide analogs and mapped using directed mutagenesis [25].

Given its catalytic activity and ligand recognition properties, DNPH1 can be considered to be a catabolic enzyme potentially involved in the maintenance of the balanced pool of nucleotides or in a detoxification process of modified nucleotides. Indeed, the structure of rat DNPH1 in solution [26,27] showed a largely open active site in the presence or absence of GMP. More recently, high-resolution crystal structures revealed how DNPH1 can accommodate distinct nucleotides such as the N^6 -cyclopentyl AMP and the triciribine 5'-monophosphate used in anti-cancer therapies. This suggested that phytohormonal cytokinins may also target DNPH1.

Here, we report that various N^6 -substituted AMP including some cytokinin derivatives inhibit mammalian DNPH1s, specifically rat and human DNPH1s, with affinity in the micromolar range. The X-Ray structures of three of these derivatives in complex with a recombinant variant of rat DNPH1 reveal the mechanism of the ligand recognition and suggest several routes for further optimization.

Materials and Methods

Chemicals

2'-Deoxyguanosine 5'-monophosphate was purchased from Sigma-Aldrich. N^6 -Isopentenyl adenosine 5'-monophosphate (1), *trans*-zeatin riboside 5'-monophosphate (2), *cis*-zeatin riboside 5'-monophosphate (3), dihydrozeatin riboside 5'monophosphate (4), kinetin riboside 5'-monophosphate (5) and N^6 -benzyladenosine 5'-monophosphate (6) were from OlChemIm Ltd (Czech Republic). N^6 -cyclopentyladenosine 5'monophosphate (7) was from BioLog (Germany).

General synthetic methods

Reagents and anhydrous solvents were obtained from commercial suppliers and used without further purification. Flash chromatography was performed using silica gel 60 (Merck). Preparative HPLC was carried out on a Perkin Elmer system (200 Pump) with a C18 reverse phase column (Kromasil, 5µm 100Å, 250x10 mm) using a flow rate of 5.5 mL/min and a linear gradient of acetonitrile in 20 mM triethvlammonium acetate buffer (TEAA) at pH 7 over 20 min. ¹H, ¹³C and ³¹P NMR spectra were recorded on a Bruker Avance 400 spectrometer, operating at 400.13 MHz, 100.62 MHz and 161.62 MHz, respectively. 1H-13C-HMBC, HSQC experiments were performed for complete assignment of all signals. NMR spectra were reported in ppm (δ) and were referenced to the solvent residual signal or external standard (orthophosphoric acid for ³¹P). Coupling constants (J values) are reported in hertz. High-resolution mass spectra were recorded on a Waters Q-TOF micro MS instrument using a mobile phase of acetonitrile/water with 0.1% formic acid. The purity of all tested compounds was \geq 97% as determined by HPLC analyses using a system (Agilent 1100) equipped with a diode array detector and using a reverse phase column (C18 Kromasil, 5µm 100Å, 150×4.6 mm,) and a linear gradient of acetonitrile in 10 mM TEAA buffer over 20 min at a flow rate of 1 mL/min. Retention time (R_t) and gradient elution are given.

Synthesis of N⁶-alkyladenosine 5'-monophosphates (8-14)

AMP derivatives were synthesized in two steps from 6chloropurine riboside according to reported procedures [28,29] Thus, 6-chloropurine riboside (58 mg, 0.2 mmol) was heated with an excess of the appropriate amine (3 equiv) in the presence of triethylamine (3 equiv) or calcium carbonate (3 equiv) for amines bearing an acid group at 60°C in absolute ethanol (2 mL). After evaporation of the volatiles, the crude mixtures were purified by flash chromatography on silica gel (eluent: 5% MeOH in dichloromethane) to afford the corresponding N^6 -alkyladenosines. The 5'-phosphorylation of N^6 -alkyladenosines (0,15 mmol) with POCI₃ (3 equiv) in PO(OEt)₃ (0.5 mL) at 4°C overnight afforded after purification by HPLC the expected nucleotides as triethylammonium salt. AMP derivatives **8-14** were isolated as sodium salt by ion exchange with Dowex 50W resin (Na⁺ form) in high purity (up to 97%).

N⁶-Cyclohexyladenosine 5'-monophosphate (8). White powder (42 mg); R_{t} = 9.42 min (10-50% of CH₃CN in 10 mM TEAA buffer); ¹H NMR (DMSO-*d*₆) δ 0.89-0.91 (m, 1H, H-4a cHex), 1.28-1.37 (m, 4H, H-2a cHex, H-3a cHex, H-5a cHex, H-6a cHex), 1.60-1.63 (m, 1H, H-4b cHex), 1.73-1.75 (m, 2H, H-3b cHex, H-5b cHex), 1.88-1.91 (m, 2H, H-2b cHex, H-6b cHex), 3.84-3.88 (m, 3H, H-5', H-1 cHex), 4.03-4.06 (m, 1H, H-4'), 4.21-4.23 (m, 1H, H-3'), 4.63 (t, J = 5.4, 1H, H-2'), 5.92 (d, $J_{1',2'}$ = 5.9, 1H, H-1'), 7.46 (d, $J_{1 \text{ cHex,NH}}$ = 8.4, 1H, NH), 8.19 (bs, 1H, H-2), 8.41 (s, 1H, H-8); ^{13}C NMR (DMSO-d_6) δ 25.4 (2C, C-3 cHex, C-5 cHex), 32.9 (2C, C-2 cHex, C-4 cHex), 64.8 (d 2 , J_{CP} = 5.1, C-5'), 66.9 (C-1 cHex), 71.5 (C-3'), 74.4 (C-2'), 84.5 (d ³, *J*_{CP} = 7.5, C-4'), 87.2 (C-1'), 119.8 (C-5), 139.3 (C-8), 145.3 (C-4), 152.8 (C-2), 155.4 (C-6); ³¹P NMR (DMSO-d₆) δ -1.18; HRMS (ESI-TOF) m/z calcd for $[C_{16}H_{24}N_5O_7P+H]^+$ 430.1492, found 430.1482.

N⁶-**Cyclobutyladenosine 5'-monophosphate (9).** White powder (6 mg); R_t = 6.02 min (10-50% of CH₃CN in 10 mM TEAA buffer); ¹H NMR (DMSO-*d*₆) δ 1.63-1.70 (m, 2H, H-3 cBu), 2.12 (bs, 2H, H-2a cBu, H-4a cBu), 2.25 (bs, 2H, H-2b cBu, H-4b cBu), 3.85 (bs, 2H, H-5'), 4.03-4.05 (m, 1H, H-4'), 4.21-4.23 (m, 1H, H-3'), 4.64 (t, *J* = 5.8, 1H, H-2'), 4.70 (bs, 1H, H-1 cBu), 5.92 (d, $J'_{1,2}$ = 5.8, 1H, H-1'), 7.95 (bs, 1H, NH), 8.19 (s, 1H, H-2), 8.45 (s, 1H, H-8); ¹³C NMR (DMSO-*d*₆) *d* 15.0 (C-3 cBu), 30.7 (2C, C-2 cBu, C-4 cBu), 52.7 (C-1 cBu), 64.7 (d ², *J*_{CP} = 5.0, C-5'), 71.6 (C-3'), 74.4 (C-2'), 84.5 (d ³, *J*_{CP} = 8.8, C-4'), 87.1 (C-1'), 120.0 (C-5), 139.6 (C-8), 146.9 (C-4), 153.0 (C-2), 155.0 (C-6); ³¹P NMR (DMSO-*d*₆) δ -1.14; HRMS (ESI-TOF) *m/z* calcd for [C₁₄H₂₀N₅O₇P+H]⁺ 402.1179, found 402.1177.

N⁶-**Cyclopropyladenosine 5'-monophosphate (10).** White powder (26 mg); R_t = 11.50 min (0-20% of CH₃CN in 10 mM TEAA buffer); ¹H NMR (DMSO-*d*₆) δ 0.60-0.63 (m, 2H, H-2a cPr, H-3a cPr), 0.70-0.75 (m, 2H, H-2b cPr, H-3b cPr), 3.09 (bs, 1H, H-1 cPr), 3.84 (bs, 2H, H-5'), 4.03-4.05 (m, 1H, H-4'), 4.21-4.23 (m, 1H, H-3'), 4.64 (t, *J* = 5.9, 1H, H-2'), 5.93 (d, *J*_{1,2'} = 5.9, 1H, H-1'), 7.86 (bs, 1H, NH), 8.24 (bs, 1H, H-2), 8.44 (s, 1H, H-8); ¹³C NMR (DMSO-*d*₆) δ 6.9 (2C, C-2 cPr, C-3 cPr), 24.8 (C-1 cPr), 64.8 (d ², *J*_{CP} = 5.0, C-5'), 71.5 (C-3'), 74.5 (C-2'), 84.6 (d ³, *J*_{CP} = 7.2, C-4'), 87.2 (C-1'), 120.2 (C-5), 139.6 (C-8), 149.9 (C-4), 153.0 (C-2), 155.3 (C-6); ³¹P NMR (DMSO-*d*₆) δ -1.14; HRMS (ESI-TOF) *m/z* calcd for [C₁₃H₁₈N₅O₇P+H]⁺ 388.1022, found 388.1026.

N⁶-**Phenyladenosine 5'-monophosphate** (11). White powder (10 mg); R_t = 8.85 min (10-50% of CH₃CN in 10 mM TEAA buffer); ¹H NMR (DMSO- d_6) δ 3.86-3.92 (m, 2H, H-5'), 4.09 (q, J = 3.3, 1H, H-4'), 4.26 (q, J = 3.2, 1H, H-3'), 4.70 (t, J = 5.5, 1H, H-2'), 6.00 (d, $J_{1,2}$ = 5.5, 1H, H-1'), 7.02-7.06 (m, 1H, H-4 Arom.), 7.31-7.35 (m, 2H, H-3 Arom., H-5 Arom.), 7.93-7.96 (m, 2H, H-2 Arom., H-6 Arom.), 8.41 (s, 1H, H-2), 8.64 (s, 1H, H-8), 9.86 (bs, 1H, NH); ¹³C NMR (DMSO- d_6) δ 64.8 (d ², J_{CP} = 4.8, C-5'), 71.5 (C-3'), 74.5 (C-2'), 84.7 (d ², J_{CP} = 7.1, C-4'), 87.4 (C-1'), 120.3 (C-5), 121.2 (2C, C-2 Arom., C-6 Arom.), 123.0 (C-4 Arom.), 128.8 (2C, C-3 Arom., C-5 Arom.), 140.1 (C-1 Arom.), 140.8 (C-8), 150.4 (C-4), 152.5 (C-2), 153.9 (C-6); ³¹P NMR (DMSO- d_6) δ 1.20; HRMS (ESI-TOF) *m/z* calcd for [C₁₆H₁₈N₅O₇P+H]⁺ 424.1022, found 424.1006.

N⁶-**Phenylethyladenosine 5'-monophosphate (12).** White powder (38 mg); R_t = 10.38 min (10-50% of CH₃CN in 10 mM TEAA buffer); ¹H NMR (DMSO-*d*₆) δ 2.95 (bs, 2H, CH₂-Ph), 3.72 (bs, 2H, CH₂-NH), 3.84-3.89 (m, 2H, H-5'), 4.03-4.07 (m, 1H, H-4'), 4.20-4.22 (m, 1H, H-3'), 4.65 (t, *J* = 5.4, 1H, H-2'), 5.93 (d, *J*_{1,2}' = 5.4, 1H, H-1'), 7.16-7.21 (m, 1H, H-4 Arom.), 7.25-7.31 (m, 4H, H-Arom.), 7.78 (bs, 1H, NH), 8.24 (s, 1H, H-2), 8.44 (s, 1H, H-8); ¹³C NMR (DMSO-*d*₆) δ 35.6 (CH₂-Ph), 41.8 (CH₂-NH), 64.8 (d ², *J*_{CP} = 4.4, C-5'), 71.5 (C-3'), 74.4 (C-2'), 84.6 (d ³, *J*_{CP} = 7.6, C-4'), 87.3 (C-1'), 119.8 (C-5), 126.5 (C-4 Arom.), 128.7 (2C, C-Arom.), 129.1 (2C, C-Arom.), 139.7 (C-8), 140.0 (C-1 Arom.), 149.6 (C-4), 153.1 (C-2), 155.7 (C-6); ³¹P NMR (DMSO-*d*₆) δ 1.08; HRMS (ESI-TOF) *m/z* calcd for [C₁₈H₂₂N₅O₇P+H]⁺ 452.1335, found 452.1329.

N⁶-(**2**-carboxyethyl)adenosine **5'-monophosphate** (13). White powder (30 mg); $R_1 = 10.70$ min (0-10% of CH₃CN in 10 mM aq TEAA buffer); ¹H NMR (MeOD- d_4) δ 2.63 (t, $J = 6.6, 2H, CH_2$ -COO), 3.90 (bs, 2H, NH-CH₂), 4.00-4.20 (m, 2H, H-5'), 4.27-4.29 (m, 1H, H-4'), 4.46 (dd, $J_{3',4'} = 3.1, J_{2',3'} = 5.1,$ 1H, H-3'), 4.70 (t, J = 5.5, 1H, H-2'), 6.14 (d, $J_{1',2'} = 5.9, 1H,$ H-1'), 8.28 (s, 1H, H-2), 8.51 (s, 1H, H-8); ¹³C NMR (MeOD- d_4) δ 37.6 (CH₂-COO), 39.6 (NH-CH₂), 65.8 (d ², $J_{CP} = 5.1, C-5'$), 72.3 (C-3'), 76.4 (C-2'), 85.9 (d ³, $J_{CP} = 8.9, C-4'$), 88.9 (C-1'), 120.5 (C-5), 140.5 (C-8), 149.5 (C-4), 153.9 (C-2), 156.0 (C-6), 179.1 (COO); ³¹P NMR (MeOD- d_4) δ 2.36; HRMS (ESI-TOF) *m/z* calcd for [C₁₃H₁₈N₅O₉P+H]⁺ 420.0920, found 420.0918.

N⁶-(3-carboxypropyl)adenosine **5'-monophosphate** (14). White powder (32 mg); R_t = 8.98 min (0-20% of CH₃CN in 10 mM TEAA buffer); ¹H NMR (D₂O) δ 1.80-2.11 (m, 2H, CH₂-CH₂-COO), 2.38 (t, *J* = 7.6, 2H, CH₂-COO), 3.63 (bs, 2H, NH-CH₂), 4.10-4.23 (m, 2H, H-5'), 4.37-4.47 (m, 1H, H-4'), 4.55 (dd, $J_{3',4'}$ = 3.7, $J_{2',3'}$ = 5.2, 1H, H-3'), 4.81 (t, *J* = 5.4, 1H, H-2'), 6.17 (d, $J_{1,2'}$ = 5.7, 1H, H-1'), 8.27 (s, 1H, H-2), 8.48 (s, 1H, H-8); ¹³C NMR (D₂O) δ 28.1 (CH₂-CH₂-COO), 37.2 (CH₂-COO), 43.2 (NH-CH₂), 66.9 (d ², J_{CP} = 4.9, C-5'), 73.1 (C-3'), 77.0 (C-2'), 86.6 (d ³, J_{CP} = 8.7, C-4'), 89.6 (C-1'), 121.5 (C-5), 141.8 (C-8), 150.6 (C-4), 155.3 (C-2), 157.1 (C-6), 185.0 (COO); ³¹P NMR (D₂O) δ 2.18; HRMS (ESI-TOF) *m/z* calcd for [C₁₄H₂₀N₅O₉P+H]⁺ 434.1077, found 434.1062.

Cloning, Overexpression and Purification of the Nterminal His-tagged DNPH1s

The human *dnph1* gene was amplified from the mammalian gene ATCC® Number: MGC-19540 using oligonucleotides olhumrcInde: 5'-ATGAATTCCATATGGCTGCTGCCATGGTGCCG-3' and olhumrcIHind 5'-CCCAAGCTTTCAAGTGGTTGGGTCAGGGGAG -3' in a

standard PCR reaction. The PCR product was digested with Ndel and HindIII, purified and ligated to pET28a digested with the same restriction enzymes. After transformation into E.coli DH5a strain, the plasmid DNA of several colonies was extracted and purified and sequenced. The pET28a rat dnph1 [24] and pET28a human dnph1 plasmids were used to transform E.coli Bli5 strain. Culture conditions and induction were performed as described by Konto-Ghiorghi et al [24]. Frozen cells resuspended in 40 mL of extraction/wash buffer (50 mM Na₂HPO₄, NaH₂PO₄, 300 mM NaCl pH 7.0) were lysed using a French press at 14000 p.s.i. The lysate was centrifuged at 25000 g for 30 min at 4°C. The supernatant was loaded on a 6 mL TALON (BD Bioscience) resin column previously equilibrated with the same buffer. After washing, DNPH1 was eluted with 150 mM imidazole. Fractions containing DNPH1 were pooled and dialyzed against so50 mM Na₂HPO₄, NaH₂PO₄, pH 6.0). The purity was checked by SDS PAGE electrophoresis and by measuring the specific activity. Purified His-tagged DNPH1s in 50 mM sodium phosphate buffer, pH 6.0, were stored at -20°C.

Kinetic measurements

The enzymatic activity of the rat DNPH1 (5 µM) was determined spectrophotometrically by incubating the enzyme with dGMP (100 μ M) and by following the production of 2deoxyribose 5-phosphate as described previously [24]. The activity of human DNPH1 was determined by incubating the enzyme (14 µM) with dGMP (200 µM) and by following the production of guanine (G) by RR-HPLC on a C18 reverse phase column (ZORBAX Eclipse XDB-C18, 2.1x50 mm, 1.8 µm) using a flow rate of 0.25 mL/min and a 1-12% linear gradient of acetonitrile in 20 mM TEAA buffer at pH 7 over 3.50 min. The retention time of G is 1 min and that of dGMP is 2.8 min. The initial velocity of the reaction was measured either at a variable concentration of dGMP, both in the absence and presence of inhibitors, or at a fixed concentration of dGMP and variable concentrations of inhibitors, allowing investigation of the nature of the inhibition, i.e. competitive in all cases.

Isothermal titration calorimetry

ITC was performed in a MicroCal VP-ITC calorimeter at 25°C. Protein samples were prepared as indicated above except that they were further purified by gel filtration on a Superdex 200 column. Following thermal equilibration, titrant additions were made at 600-s intervals to the 1.41 mL protein samples by adding 5 μ L aliquots of 300 μ M compounds to protein samples ([DNPH1] = 15 μ M) in 25 mM Na₂HPO₄, NaH₂PO₄, pH 6.0, 25 mM NaCl and 2 mM Tris[2-carboxyethyl] phosphine (TCEP). In the case of compound **14** (K_i = 11.2 μ M), a concentration of 1 mM was used and [DNPH1] = 20 μ M. The heat of dilution obtained from injecting the ligand into buffer was substracted before fitting. Heat effects were integrated with ITC Origin 7.0 software and a best fit was found using a single binding-site model.

Crystallization and structure refinement

Crystal growth conditions have been previously described [18] and are briefly reported here. They were refined from a primary sparse screen, Anions, pHClear and (NH₄)₂SO₄ from Qiagen. Starting from selected conditions, having the best crystal-diffraction quality, further refinement was done with 1.1 to 1.3 M (NH₄)₂SO₄ and 1.2 to 1.4 M Li₂SO₄, in mild basic buffer (100 mM Tris pH 7.4 to 8.0) at the protein concentration of 12 mg/mL in 50 mM citrate buffer pH 7.5, which gave rise to diffracting crystals from 2.0 and up to 1.6 Å resolution of rat DNPH1 in complex with the compounds 1, 5, 7 and 12. The other compounds, 8, 9, 10, 11 and 13 failed to co-crystallize and our attempts to soak those ligands failed to displace the original one. The crystal structures were solved by molecular replacement using Molrep [30] and as a template the recently solved dimeric structure of rat DNPH1 (PDB4FYI; [18]). The first refinement steps of the structures of Rat DNPH1 in complex with 1, 5 and 7 were performed using Refmac5 [31] with iterative model building of the protein alone using Coot [32]. The ligand chemical structures were designed using the PRODRG server [33] and were placed in the density. Water molecules were added automatically using Coot and the structures of the complexes were further refined using Refmac5. Space groups and refinement statistics are given in Table 1.

Results

Catalytic activity of human DNPH1

Since the majority of data concerning DNPH1 were performed with human cells, tissues and tumors, we decided to purify and characterize the human DNPH1.

Initial velocity experiments were carried out at variable concentrations of the six 2'-deoxynucleoside 5'monophosphates, dAMP, dCMP, dGMP, dIMP, dTMP and dUMP (Table 2). The kinetic parameters indicate that human DNPH1 has a K_m of 57 µM for dGMP, and a V_{max} of 0.005 units.mg⁻¹ corresponding to a k_{cat} of 0.002 s⁻¹. As reported previously for the rat DNPH1 enzyme [24], purine deoxynucleotides have a higher affinity for the human DNPH1 than pyrimidine deoxynucleotides. The K_m of human DNPH1 for dCMP (2.5 mM), dUMP (7.8 mM) and dTMP (23 mM) are high compared to dGMP (57 µM), dAMP (97 µM) and dIMP (104 μ M). Whereas rat and human DNPH1s have different k_{cab} they have similar K_m values. These differences of k_{cat} should be interpreted with caution since both enzymes were produced in Escherichia coli. However, we cannot exclude that posttranslational modifications enhance or regulate the enzymatic activity in the cellular context.

These data showed, however, that both enzymes possess rather similar functional features in agreement with their highly similar sequences (Figure 1). This observation validates the use of rat DNPH1 to study the protein-ligand interactions by Xray crystallography (see below).

DNPH1 inhibition by cytokinin ribosides 5'monophosphates (1-6) and related N⁶-substituted AMP derivatives (7-14)

We have previously shown that purine ribonucleotides inhibit the rat DNPH1 enzyme and that small substituents on the purine ring are well tolerated [25]. Structure elucidation of the
 Table 1. Data collection, phasing, and refinement statistics for rat DNPH1 structures.

	DNPH1-7	DNPH1-1	DNPH1-5
Beamline	ID14-4	FIP-BM30	ID23-2
No. of crystals	1	1	1
Space group	<i>P</i> 12 ₁ 1	<i>P</i> 12 ₁ 1	<i>P</i> 12 ₁ 1
Unit-cell parameters			
a (Å)	32.7	32.2	32.2
b (Å)	100.6	96.6	95.5
c (Å)	79.7	79.0	79.3
ß (°)	101.8	101.6	101.6
No. molecules in			
asymmetric unit	4	4	4
Wavelength (Å)	0.9795	0.9798	0.8726
Resolution (Å)	1.69 (1.79-1.69)	2.24 (2.39-2.24)	1.90 (2.00-1.90)
Rmerge (%)#	6.5 (11.5)	5.0 (10.7)	8.6 (35.6)
<i ol=""></i>	5.4 (2.6)	11.1 (6.7)	7.9 (2.1)
Completeness (%) [†]	93.8 (75.8)	92.0 (65.4)	98.6 (96.6)
Multiplicity [†]	3.9 (2.8)	3.4 (2.8)	2.2 (2.1)
Wilson B factor (Å ²)	14.9	17.2	14.6
Refinement			
Resolution (Å)	27.02-1.69	38.71-2.24	23.86-1.90
No. of reflections	50316	19911	33689
Rwork/Rfree (%) [‡]	17.6/21.2	17.4/22.7	23.2/28.6
No. Atoms			
Protein	4377	4274	4176
Ligand	112	116	112
lons	10	-	-
Water	497	183	243
B factors (Å ²)			
Protein	15.3	15.6	16.9
Ligand	15.3	17.0	15.0
lons	53.7	-	-
Water	28.1	19.0	24.1
R.m.s deviations §			
Bond lengths (Å)	0.009	0.008	0.009
Bond angles (°)	1.41	1.15	1.90
Ramachandran (%)			
most favoured	92.7	93.5	92.8
additional allowed	7.3	6.5	7.2
disallowed regions	0	0	0

†. Values in parenthesis stands for the outer shell of resolution range.

‡. Rfree is calculated on a subset of reflections that are not used in the refinement (5 %).

§. Deviation from ideal values.

doi: 10.1371/journal.pone.0080755.t001

rat DNPH1 prompted us to investigate the impact of larger substituents in position N6 of AMP on the binding affinity for mammalian DNPH1 enzymes.

Different cycloalkyls, saturated and unsaturated alkyl chains with aromatic or functional groups were considered at the N6 position. As summarized in Figure 2, all tested compounds are better inhibitors than AMP (K_i = 40 µM) [25], with inhibition



Figure 1. Sequence alignment of animal DNPH1s. Sequences of DNPH1 enzymes from various species (ranging from human to fish) have been refined using ViTO (39) to take into account the known crystal structures of the rat DNPH1. Secondary structures are shown above the sequence alignment. Sequence numbering corresponds to the rat sequence. Black circles underline the regions deleted in the crystallized recombinant enzyme. Open circles underline the long flexible loop surrounding the nucleotide binding site. Black arrows indicate the position of the residues (I18', R19', F64', I65', Q68) whose side chains interact with the *N*⁶-substituents in the solved crystal structures. The figure was generated by ESPRIPT (40).

Table 2. Kinetic parameters of the human DNPH1 withdifferent2'-deoxynucleosides5'-monophosphatesassubstrates.

	<i>k_{cat}</i> (10 ⁻³ s ⁻¹)	<i>K_m</i> (mM)	<i>k_{cat} /K_m</i> (M ⁻¹ . s ⁻¹)
dGMP	2.0 ± 0. 2	57 ± 12	35 ± 2
dAMP	2.5 ± 0.8	97 ± 14	25 ± 2
dIMP	1.6 ± 0.1	104 ± 19	15 ± 3
dCMP	8.3 ± 0.4	2500 ± 207	3.3 ± 0.3
dUMP	200 ± 20	7800 ± 1760	25 ± 6
dTMP	25 ± 2	23000 ± 3050	1.0 ± 0.2

 $K_{\rm m}$ were obtained from double reciprocal plots of initial velocity measurements. For each dNMPs five different concentrations were used.

doi: 10.1371/journal.pone.0080755.t002

potencies in the micromolar range against rat DNPH1 (K_i ranging from 1.2 to 15.5 μ M depending on the substitution).

The size of the cycloalkyl group (from 3- to 6- membered ring) appears to have little influence on the inhibition potency, as well as the nature of aromatic rings (methylfuryl **5**, benzyl **6**, and phenylethyl **12**), as confirmed by the similar K_i values (from 1.8 to 2.3 μ M). Surprisingly, AMP bearing a phenyl ring (compound **11**) revealed a moderate K_i (10.6 μ M) illustrating the benefit of a methylene group between N6 and the cycloalkyl or aromatic group.

All these substitutions significantly improved the inhibition potency towards rat DNPH1 as compared to AMP (up to 40

fold higher). This could be explained by a contribution of the hydrophobic substituents.

By contrast, the presence of polar functional groups (such as alcohol or carboxylic acid) significantly decreased the inhibition of DNPH1s. Indeed, whereas compound **1** is a good inhibitor (K_i of 3.3 and 2.0 μ M for rat and human DNPH1, respectively), the presence of a hydroxyl group on the C4 chain (zeatin derivatives **2**, **3** and **4**) resulted in a significant decrease in activity (up to 5-fold for **2** compared to **1**).

These results were quite surprising regarding the largely solvent-accessible active site where the nucleobase is sandwiched between two hydrophobic isoleucine residues (I18 and I65) while its N1/N6 edge faces the solvent [18].

Binding affinity of the N⁶-substituted AMP derivatives

To further characterize the ligand-DNPH1 interactions, the thermodynamic binding parameters of some N^6 -substituted AMP derivatives to rat and human DNPH1s were determined using isothermal titration calorimetry (ITC) (Table 3). Representative ITC results and fitting curves for inhibitor **6** binding to rat and human DNPH1 are shown in Figure 3. All N^6 -substituted AMP tightly bind rat DNPH1 (K_d values ranging from 0.4 to 2.6 μ M), with the exception of **14** (K_d of 9.4 μ M). Thus, the free energies are lower as compared to GMP (-6.8 kcal mol⁻¹) [25] suggesting additional interactions with the protein. Most of the substituents at position 6 improved the enthalpic term compared to GMP [25]. The beneficial effect is more pronounced for the aromatic substituents (compounds **5**

O-P-O- O-O-O-O-O-O-O-O-O-O-O-O-O-O-O-O-O						
Compound	R	<i>K_i</i> (μM)				
1	CH3 CH3	3.3 ± 0.8	Human DNPH 1 2.0 ± 0.4			
2	CH ₂ OH	15.5 ± 1	8.0 ± 1.4			
3	сн ₂ сн ₂ он	6.1 ± 1.2	5.6 ± 0.8			
4	сн₃ сн₂он	7.6 ± 1.5	3.9 ± 1.0			
5	-5	1.8 ± 0.7	2.2 ± 0.2			
6	s S	1.8 ± 0.2	1.9 ± 0.1			
7	30	1.2 ± 0.1	2.6 ± 0.3			
8	3,C	1.2 ± 0.1	1.6 ± 0.3			
9	ъ <u>⊢</u>	1.3 ± 0.1	1.5 ± 0.1			
10	35	2.0 ± 0.6	2.8 ± 0.6			
11	4	10.6 ± 0.5	11.2 ± 0.5			
12	Lev.	2.9 ± 0.3	$\textbf{7.8}\pm\textbf{1.0}$			
13	.ş./Кон	6.2 ± 0.7	5.6 ± 0.5			
14	.§_∕_он	11.2 ± 0.8	2.1 ± 0.2			

Figure 2. DNPH1 inhibition by cytokinin ribosides 5'monophosphates and *N*⁶-substituted AMP. doi: 10.1371/journal.pone.0080755.g002

and **6**). By contrast, no gain in entropy was observed. Only the cyclopentyl group (compound **7**) showed a favorable entropic contribution, although the Δ S term remains negative.

These binding parameters are very similar to those obtained with human DNPH1 (Table 3).

In order to diminish the experimental constraints on ITC measurements, the thermodynamic data were transformed into $\Delta\Delta$ -plots according to Olsson [34]. A strict compensation is observed since $T\Delta\Delta S \approx \Delta\Delta H$ and consequently $\Delta\Delta G \approx 0$ (Figure 4). Thus, there is no gain of ΔG for any of the ligand and no significant change in the order of magnitude of K_d .

In an attempt to rationalize these biochemical and thermodynamic data, a structural study was performed.

Crystal structure of rat DNPH1 in complex with N⁶substituted AMP derivatives

In a previous study, we solved the crystal structure of rat DNPH1 bound to three distinct nucleotide analogs [18]. These crystal structures revealed the tight recognition of the phosphate group as well as the ribose moiety of the nucleotide by DNPH1. Indeed, an intricate network of several hydrogen bonds formed between the phosphate group and the protein

Table 3. Dissociation constants K_d of human and rat DNPH1 with some cytokinin ribosides 5'-monophosphates and N^6 -substituted AMP as ligands at T = 298 K.

Rat				-T∆S	$\Delta \mathbf{G}$
DNPH1	<i>K</i> d(μM)	∆H(kcal.mol ⁻¹)	∆S(cal.K ¹ .mol ⁻¹)	(kcal.mol ⁻¹)	(kcal.mol ⁻¹)
1	2.6 ± 0.1	-15.9 ± 0.1	-27.9	8.3	-7.6
5	0.8 ± 0.1	-25.7 ± 0.1	-58.3	17.4	-8.3
6	0.4 ± 0.1	-27.4 ± 0.1	-62.4	18.6	-8.8
7	0.6 ± 0.1	-10.7 ± 0.1	-7.5	2.3	-8.5
8	0.5 ± 0.1	-19.9 ± 0.1	-37.6	11.2	-8.7
14	9.4 ± 0.1	-12.4 ± 0.1	-18.5	5.5	-6.9
human	K _d	$\Delta \mathbf{H}$	ΔS	-T∆S	$\Delta \mathbf{G}$
DNPH1	(µM)	(kcal.mol ⁻¹)	(cal.K ⁻¹ .mol ⁻¹)	(kcal.mol ⁻¹)	(kcal.mol ⁻¹)
1	2.1 ± 0.2	-10.2 ± 0.1	-8.2	2.4	-7.8
5	1.4 ± 0.1	-20.1 ± 0.1	-42.4	12.6	-7.5
6	0.7 ± 0.1	-26.1 ± 0.1	-59.5	17.7	-8.4
7	1.4 ± 0.4	-6.1 ± 0.1	6.2	-1.8	-8.0
14	5.5 ± 0.1	-9.8 ± 0.1	-8.8	2.6	-7.2

Data were collected in 25 mM Na2HPO4, NaH2PO4, pH 6.0, 25 mM NaCl, 2mM Tris[2-carboxyethyl] phosphine (TCEP) and [DNPH1] = 15 μ M, [compounds] = 300 μ M except for [compound **14**] = 1 mM and [DNPH1] = 20 μ M. Data were corrected for ligand heats of dilution and deconvoluted using the Microcal Origin software. The results of the least-squares fit assuming a single site binding model are displayed. Experiments were done in duplicate.

doi: 10.1371/journal.pone.0080755.t003

that involves the side chains of two serines (Ser87 and Ser17') and the backbone N atoms of IIe18, Arg19, Gly20 and Gly89. The ribose tightly interacts with Gly16, Gly89, Glu93 and Met119'. The two hydroxyls O2' and O3' atoms of the ribose are hydrogen-bonded to the carboxylate group of Glu93. This indicates that there is apparently little room for chemical variations in this part of the ligand to improve the affinity for this target. In parallel, these complexes have revealed that the N6 position was amenable to significant substitutions. However, as discussed above, the rationale to further guide the design of enhanced inhibitors was not obvious. The crystal structure of some cytokinins (or close analogs) bound to rat DNPH1 was expected to provide brighter insights.

High-resolution data were obtained for three complexes while the other ligands failed to provide us with decent crystals. The new structures were all obtained in the same monoclinic space group ($P12_11$) that differs from the orthorhombic form previously described despite the similar conditions used to grow the crystals. These results suggest that we can survey



Figure 3. Representative isothermal titration of rat (left) and human (right) DNPH1with inhibitor 6, best-fitted with onesite binding model.

doi: 10.1371/journal.pone.0080755.g003

the impact of the different crystal packing on the protein conformation. Having one complex - rat DNPH1-7 - in common in the two available space groups, we could conclude that the absence of electron density for the long loop (residues 47-59) was due to its intrinsic flexibility rather than packing issue. This is in agreement with published NMR data [27]. This is reinforced by the observed flexibility of this loop in the four independent monomers in the asymmetric unit of both space groups. This particular feature may explain the small influence of the N^6 -substituent on the inhibitory activity of the various cytokinins against DNPH1.

Indeed, the three novel crystal structures showed little structural variation for protein structure. The two dimers in the asymmetric unit from these three crystal structures can be superimposed (as exemplified in Figure 5) with an averaged r.m.s.d. of 0.5 Å, only slightly above the experimental error (~0.3 Å). In all these structures, the phosphate groups and the ribose moieties showed the same tight interactions with the protein side chains and backbone atoms as previously described [18]. Similarly, the adenine moiety showed a conserved orientation constrained by the two sandwiching isoleucines I18 and I65 in the three complexes. Conversely, the three distinct N⁶-derivatizations appeared to be mobile in the crystal structures and to occupy distinct locations depending on the monomer considered. Two main families of orientation are detected whatever the chemical derivatization (isopentenyl, furfuryl and cyclopentyl). In some monomers, the N⁶substitution points toward a hydrophobic subpocket formed by the side chain of isoleucine I18 and part of the side chain of arginine R19 (Figure 6a, b and c) while in other monomers, the substitution points rather outward and interacts mainly with isoleucine I65 and rather weakly with the glutamine Q68 in the case of compound 5 (Figure 6d, 6e and 6f). Accordingly, whatever the Nº-substitution, rather weak van der Waals



Figure 4. $\Delta\Delta H$ versus $-T\Delta\Delta S$ plot of experimental differences, compiled from the ITC data of Table 3 at 298 K, for pairs of ligands binding to human DNPH1 (open circles) and rat DNPH1 (black squares). The line corresponds to full enthalpy-entropy compensation ($\Delta\Delta H = T\Delta\Delta S$).

doi: 10.1371/journal.pone.0080755.g004

contacts are observed and little stabilization of the complexes occurred. As the three distinct complexes are likely to represent good templates for the modeling of the binding mode



Figure 5. Superposed crystal structure of rat DNPH1 in complex with nucleotides *N*⁶-cyclopentyl AMP, *N*⁶-furfuryl AMP and *N*⁶-isopentenyl AMP (compounds numbered 7, 5 and 1 in the text, respectively). One dimer of each complex is shown in blue/ green ribbons. The corresponding ligands are shown as orange sticks. The figures were generated by Pymol (www.pymol.org). doi: 10.1371/journal.pone.0080755.g005

of the other ligands studied here (with **7** for cycloalkyl, **5** for aromatic cycles and **1** for alkyl substituents), one may conclude that alternating conformations can be predicted for all the N^{6} -substituted AMP bound to mammalian DNPH1. None of the tested substition can fit a buried sub-pocket to maximize additional interactions. This suggests that the few favorable interactions observed in one configuration or another (inward for 7 or 1 and outward for **5**) are not sufficient to dramatically alter the binding affinity. This is in agreement with our thermodynamic data (compiled in Table 3) showing enthalpy-entropy compensation. Any additional but weak interactions made at the surface of the protein by a given N^{6} -substituent are counterbalanced by the entropy cost of its stabilization (or desolvatation in some cases such as compound **5**) in one orientation.

Discussion

The three related phytohormones, N^6 -isopentenyladenosine, N^6 -benzyladenosine and N^6 -furfuryladenosine display anticancer activity both *in vitro* and *in vivo* and induce apoptosis through caspase-3 activation [4,5]. These nucleoside derivatives do not act by interfering with DNA synthesis as most other nucleoside analogs; rather, they accumulate intracellularly as mononucleotides (the di- and tri-phosphate being traces) [14,35]. This particular mode of action resembles that described for triciribine [15,16].

Nevertheless, the actual molecular targets are still unknown and the precise mechanism of action of these cytokinin ribosides remains to be determined. By similarity with triciribine, Akt might be one possible target. Indeed, N^{6} -



Figure 6. The active site of the DNPH1 structures in complex with nucleotides N^6 -cyclopentyl AMP (A, D), N^6 -furfuryl AMP (B, E) and N^6 -isopentenyl AMP (C, F). The ligand conformers correspond to two independent monomers in the crystal structures of rat DNPH1 in the monoclinic forms (this study; panels A, B, C, E, and F) and the previously published orthorhombic form (PDB4FYI) in the first panel D). Omit maps were computed by omitting the ligand at the last refinement step before computing the electron density. The density of the bound ligands were contoured at the 1.0 s level and shown as orange surfaces and meshes. Backbones are represented as ribbons (front monomer in green and back monomer in blue) and ligands as sticks. Important side chains were drawn as sticks. Side chains contacting the N^6 -substituents (I18, R19, F64, I65 and Q68) are shown in pink and some other residues that make up the active site (S17, D62, W72) are in green. The figures were generated by Pymol (www.pymol.org). doi: 10.1371/journal.pone.0080755.g006

isopentenyladenosine suppresses the nuclear factor kappaB (NF- κ B) pathway and inhibits the Akt activation [36].

The kinetic, thermodynamic and structural data reported here indicate that DNPH1 may be a potential cytokinin target. Some cancer cell lines are killed by cytokinins at low micromolar concentrations [37,38], a concentration range that inhibits the activity of DNPH1. The differences of values between the lethal concentrations in the different cell lines and the K_i values for DNPH1 may be explained by the phosphorylation capacity of ADK [14], the existence of an adenosine deaminase-like enzyme ADAL1 that catalyzes the removal of different alkyl groups at position 6 from N^6 -substituted purine and 2-aminopurine nucleosides 5'-monophosphates [39] and the level of *dnph1* expression.

It is likely that cytokinins may also bind other targets such as the lactate dehydrogenase LDH-A, which is the form of LDH expressed in many cancer cells [40]. It is interesting to note that inhibition of LDH-A slows the growth of xenografts tumours in mice and induces tumour regression [41]. Whereas the overexpression of DNPH1 nor LDH-A alone do not induce tumorigenesis, cells expressing both DNPH1 and LDH-A form tumors after injection into nude mice [42]. It is therefore tempting to hypothesize that N^6 -substituted AMP derivatives might have to inhibit both DNPH1 and LDH-A to efficiently inhibit cell growth.

Another argument in favor of other targets than DNPH1 for the inhibition of cell growth is, for example, provided by the identification of human tyrosyl-DNA phosphodiesterase 1 (TDP1), SMAD3 or PAX8 with micromolar affinity for *ortho*topolin riboside, the most active cytokinin reported so far, (See Pubchem CID 13506406 Compound BioActivity Data). These data suggest that an intricate network of activation and inhibition may play a role in the anti-cancer activity of triciribine or other nucleoside analogs such as cytokinins.

Stringent affinity chromatography or drug affinity responsive target stability (DARTS) may help to identify cytokinin protein targets [43].

Our current study shows that cytokinin ribosides 5'monophosphates inhibit mammalian DNPH1. Thermodynamic and structural characterization of DNPH1 in complex with N° substituted AMP suggests further modifications. Derivatizations at the N6 position are currently underway and are expected to compensate the observed alternation in binding modes. These chemical tools will contribute to elucidate the role of DNPH1 in cellular proliferation.

Acknowledgements

The authors would like to thank Valérie Huteau for their technical contribution, Miroslav Strnad for *ortho*-Topolin riboside 5'-monophosphate gift, Patrick England and Sylviane Hoos for their help for isothermal titration calorimetry, Jason Bland and Frederick Saul for proofreading.

Author Contributions

Conceived and designed the experiments: CA SP AP GL PAK. Performed the experiments: CA AP GL PAK. Analyzed the data: CA SP AP GL PAK. Wrote the manuscript: SP GL PAK.

References

- Sampath D, Rao VA, Plunkett W (2003) Mechanisms of apoptosis induction by nucleoside analogs. Oncogene 22: 9063-9074. doi: 10.1038/sj.onc.1207229. PubMed: 14663485.
- 2. Parker WB (2009) Enzymology of Purine and Pyrimidine Antimetabolites Used in the Treatment of Cancer. Chem Rev 109: 2880-2893. doi:10.1021/cr900028p. PubMed: 19476376.
- Cabello CM, Bair WB 3rd, Ley S, Lamore SD, Azimian S et al. (2009) The experimental chemotherapeutic N6-furfuryladenosine (kinetinriboside) induces rapid ATP depletion, genotoxic stress, and CDKN1A(p21) upregulation in human cancer cell lines. Biochem Pharmacol 77: 1125-1138. doi:10.1016/j.bcp.2008.12.002. PubMed: 19186174.
- Choi BH, Kim W, Wang QC, Kim DC, Tan SN et al. (2008) Kinetin riboside preferentially induces apoptosis by modulating Bcl-2 family proteins and caspase-3 in cancer cells. Cancer Lett 261: 37-45. doi: 10.1016/j.canlet.2007.11.014. PubMed: 18162289.
- Laezza Ć, Caruso MG, Gentile T, Notarnicola M, Malfitano AM et al. (2009) N6-isopentenyladenosine inhibits cell proliferation and induces apoptosis in a human colon cancer cell line DLD1. Int J Cancer 124: 1322-1329. doi:10.1002/ijc.24056. PubMed: 19058178.
- Laezza C, Malfitano AM, Di Matola T, Ricchi P, Bifulco M (2010) Involvement of Akt/NF-kappaB pathway in N6-isopentenyladenosineinduced apoptosis in human breast cancer cells. Mol Carcinog 49: 892-901. doi:10.1002/mc.20666. PubMed: 20672320.
- Spinola M, Colombo F, Falvella FS, Dragani TA (2007) N6isopentenyladenosine: a potential therapeutic agent for a variety of epithelial cancers. Int J Cancer 120: 2744-2748. doi:10.1002/ijc.22601. PubMed: 17304507.
- Dolezal K, Popa I, Hauserová E, Spíchal L, Chakrabarty K et al. (2007) Preparation, biological activity and endogenous occurrence of N6benzyladenosines. Bioorg Med Chem 15: 3737-3747. doi:10.1016/ j.bmc.2007.03.038. PubMed: 17418578.
- Cheong J, Goh D, Yong JW, Tan SN, Ong ES (2009) Inhibitory effect of kinetin riboside in human heptamoa, HepG2. Mol Biosyst 5: 91-98. doi: 10.1039/b712807j. PubMed: 19081935.
- Dudzik P, Dulińska-Litewka J, Wyszko E, Jędrychowska P, Opałka M et al. (2011) Effects of kinetin riboside on proliferation and proapoptotic activities in human normal and cancer cell lines. J Cell Biochem 112: 2115-2124. doi:10.1002/jcb.23132. PubMed: 21465535.
- Ottria R, Casati S, Baldoli E, Maier JA, Ciuffreda P (2010) N-Alkyladenosines: Synthesis and evaluation of in vitro anticancer activity. Bioorg Med Chem 18: 8396-8402. doi:10.1016/j.bmc. 2010.09.030. PubMed: 21035348.
- Tiedemann RE, Mao X, Shi CX, Zhu YX, Palmer SE et al. (2008) Identification of kinetin riboside as a repressor of CCND1 and CCND2 with preclinical antimyeloma activity. J Clin Invest 118: 1750-1764. PubMed: 18431519.
- Mlejnek P (2001) Caspase inhibition and N6-benzyladenosine-induced apoptosis in HL-60 cells. J Cell Biochem 83: 678-689. doi:10.1002/jcb. 1262. PubMed: 11746510.
- Mlejnek P, Dolezel P (2005) Apoptosis induced by N6-substituted derivatives of adenosine is related to intracellular accumulation of corresponding mononucleotides in HL-60 cells. Toxicol In Vitro 19: 985-990. doi:10.1016/j.tiv.2005.06.023. PubMed: 16181767.
- Bennett LL Jr., Smithers D, Hill DL, Rose LM, Alexander JA (1978) Biochemical properties of the nucleoside of 3-amino-1,5-dihydro-5methyl-1,4,5,6,8-pentaazaacenaphthylene (NSC-154020). Biochem Pharmacol 27: 233-241. doi:10.1016/0006-2952(78)90306-4. PubMed: 564191.
- Plagmann PG (1976) Transport, phosphorylation, and toxicity of a tricyclic nucleoside in cultured Novikoff rat hepatoma cells and other cell lines and relase of its monophosphate by the cells. J Natl Cancer Inst 57: 1283-1295. PubMed: 187799.
- Garrett CR, Coppola D, Wenham RM, Cubitt CL, Neuger AM et al. (2011) Phase I pharmacokinetic and pharmacodynamic study of triciribine phosphate monohydrate, a small-molecule inhibitor of AKT phosphorylation, in adult subjects with solid tumors containing activated AKT. Invest New Drugs 29: 1381-1389. doi:10.1007/ s10637-010-9479-2. PubMed: 20644979.
- Padilla A, Amiable C, Pochet S, Kaminski PA, Labesse G (2013) Structure of the oncoprotein Rcl bound to three nucleotide analogues. Acta Crystallogr D Biol Crystallogr 69: 247-255. doi:10.1107/ S0907444912045039. PubMed: 23385460.
- Lewis BC, Prescott JE, Campbell SE, Shim H, Orlowski RZ et al. (2000) Tumor induction by the c-Myc target genes rcl and lactate dehydrogenase A. Cancer Res 60: 6178-6183. PubMed: 11085542.

- Lewis BC, Shim H, Li Q, Wu CS, Lee LA et al. (1997) Identification of putative c-Myc-responsive genes: characterization of rcl, a novel growth-related gene. Mol Cell Biol 17: 4967-4978. PubMed: 9271375.
- Rhodes DR, Barrette TR, Rubin MA, Ghosh D, Chinnaiyan AM (2002) Meta-analysis of microarrays: interstudy validation of gene expression profiles reveals pathway dysregulation in prostate cancer. Cancer Res 62: 4427-4433. PubMed: 12154050.
- Shin S, Bosc DG, Ingle JN, Spelsberg TC, Janknecht R (2008) Rcl is a novel ETV1/ER81 target gene upregulated in breast tumors. J Cell Biochem 105: 866-874. doi:10.1002/jcb.21884. PubMed: 18726892.
- Gorgun G, Ramsay AG, Holderried TA, Zahrieh D, Le Dieu R et al. (2009) E(mu)-TCL1 mice represent a model for immunotherapeutic reversal of chronic lymphocytic leukemia-induced T-cell dysfunction. Proc Natl Acad Sci U S A 106: 6250-6255. doi:10.1073/pnas. 0901166106. PubMed: 19332800.
- Ghiorghi YK, Zeller KI, Dang CV, Kaminski PA (2007) The c-Myc target gene Rcl (C6orf108) encodes a novel enzyme, deoxynucleoside 5'monophosphate N-glycosidase. J Biol Chem 282: 8150-8156. doi: 10.1074/jbc.M610648200. PubMed: 17234634.
- Dupouy C, Zhang C, Padilla A, Pochet S, Kaminski PA (2010) Probing the Active Site of the Deoxynucleotide N-Hydrolase Rcl Encoded by the Rat Gene c6orf108. J Biol Chem 285: 41806-41814. doi:10.1074/ jbc.M110.181594. PubMed: 20962348.
- Doddapaneni K, Mahler B, Pavlovicz R, Haushalter A, Yuan C et al. (2009) Solution structure of RCL, a novel 2'-deoxyribonucleoside 5'monophosphate N-glycosidase. J Mol Biol 394: 423-434. doi:10.1016/ j.jmb.2009.08.054. PubMed: 19720067.
- Yang Y, Padilla A, Zhang C, Labesse G, Kaminski PA (2009) Structural characterization of the mammalian deoxynucleotide N-hydrolase Rcl and its stabilizing interactions with two inhibitors. J Mol Biol 394: 435-447. doi:10.1016/j.jmb.2009.10.004. PubMed: 19822152.
- Fleysher MH, Bernacki RJ, Bullard GA (1980) Some Short-Chain N6-Substituted Adenosine-Analogs with Anti-Tumor Properties. J Med Chem 23: 1448-1452. doi:10.1021/jm00186a031. PubMed: 7452700.
- Jiang H, Kim JH, Frizzell KM, Kraus WL, Lin H (2010) Clickable NAD analogues for labeling substrate proteins of poly(ADP-ribose) polymerases. J Am Chem Soc 132: 9363-9372. doi:10.1021/ja101588r. PubMed: 20560583.
- Vagin A, Teplyakov A (2010) Molecular replacement with MOLREP. Acta Crystallogr D Biol Crystallogr 66: 22-25. doi:10.1107/ S0108767309045206. PubMed: 20057045.
- Murshudov GN, Vagin AA, Dodson EJ (1997) Refinement of macromolecular structures by the maximum-likelihood method. Acta Crystallogr D Biol Crystallogr 53: 240-255. doi:10.1107/ S0907444996012255. PubMed: 15299926.
- Emsley P, Cowtan K (2004) Coot: model-building tools for molecular graphics. Acta Crystallogr D Biol Crystallogr 60: 2126-2132. doi: 10.1107/S0907444904019158. PubMed: 15572765.
- Schüttelkopf AW, van Aalten DM (2004) PRODRG: a tool for highthroughput crystallography of protein-ligand complexes. Acta Crystallogr D Biol Crystallogr 60: 1355-1363. doi:10.1107/ S0907444904011679. PubMed: 15272157.
- Olsson TS, Ladbury JE, Pitt WR, Williams MA (2011) Extent of enthalpy-entropy compensation in protein-ligand interactions. Protein Sci 20: 1607-1618. doi:10.1002/pro.692. PubMed: 21739503.
- McDermott SP, Eppert K, Notta F, Isaac M, Datti A et al. (2012) A small molecule screening strategy with validation on human leukemia stem cells uncovers the therapeutic efficacy of kinetin riboside. Blood 119: 1200-1207. doi:10.1182/blood-2011-01-330019. PubMed: 22160482.
- Laezza C, Malfitano AM, Di Matola T, Ricchi P, Bifulco M (2010) Involvement of Akt/NF-kappa B Pathway in N-6-Isopentenyladenosine-Induced Apoptosis in Human Breast Cancer Cells. Mol Carcinog 49: 892-901. doi:10.1002/mc.20666. PubMed: 20672320.
- Voller J, Zatloukal M, Lenobel R, Dolezal K, Béres T et al. (2010) Anticancer activity of natural cytokinins: a structure-activity relationship study. Phytochemistry 71: 1350-1359. doi:10.1016/j.phytochem. 2010.04.018. PubMed: 20553699.
- Rajabi M, Signorelli P, Gorincioi E, Ghidoni R, Santaniello E (2010) Antiproliferative Activity of N-6-Isopentenyladenosine on MCF-7 Breast Cancer Cells: Cell Cycle Analysis and DNA-Binding Study. DNA Cell Biol 29: 687-691. doi:10.1089/dna.2010.1073. PubMed: 20818975.
- Murakami E, Bao HY, Mosley RT, Du JF, Sofia MJ et al. (2011) Adenosine Deaminase-like Protein 1 (ADAL1): Characterization and Substrate Specificity in the Hydrolysis of N-6- or O-6-Substituted Purine or 2-Aminopurine Nucleoside Monophosphates. J Med Chem 54: 5902-5914. doi:10.1021/jm200650j. PubMed: 21755941.

- 40. Kaplan NO, Everse J, Dixon JE, Stolzenb, Fe et al Lee CY. (1974) Purification and Separation of Pyridine Nucleotide-Linked Dehydrogenases by Affinity Chromatography. Techniques -Proceedings of the National Academy of Sciences of the United States of America: 3450-3454 doi:10.1073/pnas.71.9.3450.
- 41. Le A, Cooper CR, Gouw AM, Dinavahi R, Maitra A et al. (2010) Inhibition of lactate dehydrogenase A induces oxidative stress and

inhibits tumor progression. Proc Natl Acad Sci U S A 107: 2037-2042. doi:10.1073/pnas.0914433107. PubMed: 20133848.

- Lewis BC, Prescott JE, Campbell SE, Shim H, Orlowski RZ et al. (2000) Tumor induction by the c-Myc target genes rcl and lactate dehydrogenase A. Cancer Res 60: 6178-6183. PubMed: 11085542.
- Lomenick B, Olsen RW, Huang J (2011) Identification of Direct Protein Targets of Small Molecules. ACS Chem Biol 6: 34-46. doi:10.1021/ cb100294v. PubMed: 21077692.